Hypertrophic cardiomyopathy
Drug research and approvals for hypertrophic cardiomyopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 77 studies of hypertrophic cardiomyopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 77
- Trials authorized in Canada: 9
- FDA orphan approvals: 3
- EU medicines: 2
Recruiting Now
Newest start dates first, of 77 recruiting on ClinicalTrials.gov ↗- Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001NCT07867288 · Phase 1 · Haya Therapeutics, Inc. · starts Oct 30, 2026
- ATR 1072 in Participants With PRKAG2 SyndromeNCT07738107 · Phase 1 / Phase 2 · Atrium Therapeutics · starts Sep 14, 2026
- BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic CardiomyopathyNCT07755904 · Phase 3 · Braveheart Bio, Inc. · starts Sep 2, 2026
- HCMR Re-Imaging StudyNCT07054073 · Not reported · Christopher Kramer · starts Jul 27, 2026
- Study of LX2006 Gene Therapy in Friedreich Ataxia CardiomyopathyNCT07721025 · Phase 2 · Lexeo Therapeutics · starts Jun 25, 2026
- A Real-World Study on Hypertrophic Cardiomyopathy in Chinese PopulationNCT06775665 · Not reported · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Jun 1, 2026
- Mechanisms of Atrial Pathoelectrophysiology in HCMNCT07454135 · Not reported · Guy's and St Thomas' NHS Foundation Trust · starts May 26, 2026
- Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic CardiomyopathyNCT07600177 · Phase 4 · Oregon Health and Science University · starts May 5, 2026
- Multicentre Hypertrophic Cardiomyopathy RegistryNCT07381894 · Not reported · University of Manchester · starts Apr 1, 2026
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH TrialNCT07120776 · Not applicable · University of Manchester · starts Mar 26, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 7, 2024 | A phase 2/3 multicenter, randomized, double-blind, placebo-controlled and open-label extension trial to evaluate the efficacy and safety of aficamten in a…AFICAMTEN (CK-3773274) | Cytokinetics | Ongoing |
| Jul 11, 2024 | A follow-up, open-label, research evaluation of sustained treatment with aficamten (ck-3773274) in hypertrophic cardiomyopathy (hcm)AFICAMTEN (CK-3773274) | Cytokinetics | Ongoing |
| May 22, 2024 | A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic…AFICAMTEN (CK-3773274) | Cytokinetics | Closed |
| Jan 26, 2024 | A randomized, double-blind, placebo-controlled clinical study to evaluate mavacamten adolescents (age 12 years to < 18 years) with symptomatic obstructive…MAVACAMTEN (BMS-986427, MYK-461) | Bristol-Myers Squibb | Ongoing |
| Aug 23, 2023 | A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to metoprolol in adults with symptomatic…AFICAMTEN (CK-3773274) / METOPROLOL | Cytokinetics | Closed |
| Dec 20, 2022 | A randomized, double-blind, placebo-controlled clinical study to evaluate mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathyMAVACAMTEN (BMS-986427, MYK-461) | Bristol-Myers Squibb | Closed |
| Dec 16, 2015 | Mobilization of endothelial progenitor cells following alcohol septal ablation in hypertrophic obstructive cardiomyopathy: randomized controlled trial of…ACETYLSALICYLIC ACID | OTTAWA HEART INSTITUTE RESEARCH CORPORATION | Pending |
| Aug 8, 2014 | Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric hcm.VALSARTAN | HOSPITAL FOR SICK CHILDREN | Closed |
| Apr 9, 2014 | Hcmr - novel predictors of outcome in hypertrophic cardiomyopathyGADOBUTROL | DR MATTHIAS FRIEDRICH | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Sep 30, 2026 | Camzyostreatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve… | MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb) | Approved |
| Dec 19, 2025 | Myqorzotreatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms | Cytokinetics Inc. | Approved |
| Apr 28, 2022 | CamzyosTreatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to… | MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb) | Approved |
| Jul 21, 2026 | S-Cibenzoline succinatetreatment of obstructive hypertrophic cardiomyopathy (oHCM) | Celltrion, Inc. | Designated |
| Jun 18, 2026 | ninerafaxstattreatment of symptomatic nonobstructive hypertrophic cardiomyopathy | Imbria Pharmaceuticals, Inc. | Designated |
| May 12, 2021 | a native AAV9 capsid with a genomic cassette containing a…Treatment of hypertrophic cardiomyopathy (HCM) due to loss-of-function mutations in the MYBPC3 gene encoding cardiac myosin-binding protein… | Tenaya Therapeutics | Designated |
| Oct 26, 2020 | DasatinibTreatment of Noonan syndrome-associated hypertrophic cardiomyopathy | IGIA Pharmaceuticals, Inc. | Designated |
| Jun 14, 2012 | perhexiline maleateTreatment of moderate to severe symptomatic hypertrophic cardiomyopathy | Heart Metabolics, Limited. | Designated |
Medicines Authorised in the EU
Newest first| Feb 12, 2026 | Myqorzoaficamten | Cytokinetics (Ireland) Limited | EMA ↗ |
| Jun 26, 2023 | Camzyosmavacamten | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA